

1 **Nutritional Assessment During a 14-d Saturation Dive: the NASA Extreme Environment**

2 **Mission Operation V Project**

3

4

5 **SM Smith, JE Davis-Street, JV Fesperman, MD Smith, BL Rice, SR Zwart**

6

7

8

9

10 **ABSTRACT**

11 Ground-based analogs of spaceflight are an important means of studying physiological and
12 nutritional changes associated with space travel, particularly since exploration missions are
13 anticipated, and flight research opportunities are limited. A clinical nutritional assessment of the
14 NASA Extreme Environment Mission Operation V (NEEMO) crew (4 M, 2 F) was conducted
15 before, during, and after the 14-d saturation dive. Blood and urine samples were collected before
16 (D-12 and D-1), during (MD 7 and MD 12), and after (R + 0 and R + 7) the dive. The foods
17 were typical of the spaceflight food system. A number of physiological changes were reported
18 both during the dive and post dive that are also commonly observed during spaceflight. Serum
19 hemoglobin and hematocrit were decreased ($P < 0.05$) post dive. Serum ferritin and
20 ceruloplasmin significantly increased during the dive, while transferrin receptors tended to go
21 down during the dive and were significantly decreased by the last day (R + 0). Along with
22 significant hematological changes, there was also evidence for increased oxidative damage and
23 stress during the dive. 8-hydroxydeoxyguanosine was elevated ($P < 0.05$) during the dive, while
24 glutathione peroxidase and superoxide dismutase activities were decreased ($P < 0.05$) during the
25 dive. Serum C-reactive protein (CRP) concentration also tended to increase during the dive,
26 suggesting the presence of a stress-induced inflammatory response. Decreased leptin during the
27 dive ($P < 0.05$) may also be related to the increased stress. Similar to what is observed during
28 spaceflight, subjects had decreased energy intake and weight loss during the dive. Together,
29 these similarities to spaceflight provide a model to further define the physiological effects of
30 spaceflight and investigate potential countermeasures.

31

32 Key words: saturation diving, hyperbaric, nutrition, spaceflight analog

33 INTRODUCTION

34 Nutrition is essential for the maintenance of crew health before, during, and after spaceflight.
35 Several physiological changes occur during spaceflight, including bone and muscle loss (1),
36 oxidative damage (2), cardiovascular, and hematologic alterations (3). These may involve
37 altered nutritional status to one degree or other. Ground-based models have been used
38 extensively to study human adaptation to spaceflight (4), including disuse (e.g., bed rest) and
39 isolation (e.g., Antarctic, closed chamber studies). Underwater analogs have also been used to
40 simulate the isolation, stress, and constraints of spaceflight. They are used to better understand
41 physiological and psychological effects on humans, to assess training and operational issues, to
42 evaluate hardware and procedures, and to test the effectiveness of potential countermeasures.

43 One underwater-based analog was named the NASA Extreme Environment Mission Operation
44 (NEEMO) project, where subjects live in an underwater habitat for extended periods of time.
45 The unique underwater laboratory provides an environment similar to that aboard the
46 International Space Station (ISS). Not only is the habitat similar in size to modules of the ISS,
47 but the “aquanauts” coordinate operations remotely via a mission control center located onshore
48 (4.5 km away), and also perform extensive science and extravehicular activities during the
49 mission. In some cases, as in the study reported here, the foods provided to the crew are the
50 same as those provided to astronauts on the ISS.

51 The environment in the habitat emulated stress-induced physiological changes commonly
52 observed during spaceflight (5) and in other ground-based analogs (6). One mechanism by
53 which physiological changes occur during spaceflight is the increased stress due to
54 environmental changes such as acceleration during lift-off, weightlessness, confinement, and
55 long-term maintenance of high levels of performance. These types of stress induce hormonal

56 changes and altered immune function (7-9). Furthermore, while these stress-induced changes are
57 known to occur during spaceflight, the confounding effects of altered nutritional status (and the
58 effects on nutritional status) are not well understood and need to be clarified in order to define
59 nutritional requirements for long-term spaceflight.

60 The aim of this study was to evaluate the nutritional status of subjects in a ground-based
61 analog of spaceflight, the fifth NEEMO mission (NEEMO V). A comprehensive nutritional
62 assessment was conducted before, during, and after the mission. We hypothesized that in
63 addition to the effects of stress and confinement, that unique characteristics of the mission and
64 habitat (e.g., increased atmospheric pressure) would also impact nutrition and health.

65

66 **METHODS**

67 *Environment*

68 NEEMO V was a 14-d saturation dive, with the crew (n = 6) living in an underwater habitat.
69 The habitat is 14 m long and 4 m in diameter (**Figure 1**). It is located 20 m (47 ft) below the
70 ocean surface, with an atmospheric pressure inside the habitat of 2.5 atm. The NEEMO V
71 mission was completed in June - July of 2003. Supplies were transferred down to the habitat via
72 sealed container, and samples were returned to the surface via the same container. All tubes and
73 hardware were pre-tested to ensure that the pressure change would not alter function. Because of
74 the nature of the dive (i.e., extended-duration saturation dive), a 17-h decompression was
75 required prior to resurfacing.

76

77 *Subjects*

78 The crew for NEEMO V consisted of 2 females and 4 males. Three of the six were astronauts
79 (one with previous flight experience), one was a scientist from the Johnson Space Center, and the
80 remaining two were technicians responsible for the maintenance of the habitat. The average age
81 was 35.7 ± 6.6 y (mean \pm SD). All subjects were required to pass an Air Force Class III physical
82 and were required to have logged a minimum of 25 dives prior to participation in the study.
83 Before the dive, the average body weight was 69.9 ± 17.3 kg. Body fat mass, bone mineral
84 content, and lean body mass were also recorded for 4 of the crewmembers (15.3 ± 2.25 , $2.51 \pm$
85 0.69 , and 52.1 ± 14.5 kg, respectively).

86 Subjects were trained on all procedures required for the successful completion of the in dive
87 sample and data collections. Pre-dive dietary data was collected from a standard food frequency
88 questionnaire (REF), while in-dive food intakes were recorded for each meal using a bar code
89 reader. Dietary training was provided by the research dietitian (BLR). Two of the crewmembers
90 were trained in phlebotomy techniques, and they subsequently collected all pre- and in-dive
91 blood samples.

92

93 *Body mass and body composition determinations*

94 Body mass was determined using a calibrated scale on the days when body composition was
95 determined, and using a standard scale on all other days. For the in-dive determinations, a
96 standard scale was tested in the habitat and was found to function reliably in the high pressure
97 atmosphere. This scale was subsequently used for the remainder of the study.

98 Body composition was determined (4 subjects only) before and after the dive using dual
99 energy x-ray absorptiometry (DEXA). Dual-energy x-ray absorptiometry (DEXA) scans were

100 performed using a Hologic QDR 4500W (Hologic, Inc., Waltham, MA) fan beam densitometer.
101 Whole body scans were performed before and after the mission for body composition
102 assessment.

103

104 *Sample Collection and Processing*

105 Blood (25.7 mL) was collected before (dive minus twelve days, D-12 and D-1), during the
106 dive [mission day 7 (MD 7) and MD 12], and post-dive (return plus zero days, designated R + 0,
107 and R + 7). For two of the subjects, the first pre-dive collection was completed at D-5/-4. Blood
108 collections were performed at the same time each day following an 8-h fast.

109 Urine was collected before (D-12, D-11, D-1; except for two subjects where samples were
110 collected on D-5, D-4, and D-1), during (MD 7, MD 12), and after the dive (R + 0, R + 1, R + 7,
111 and R + 8). Pre- and post-dive samples were collected in individual bottles and stored cool until
112 processing (<24 hours). During the dive, the crew collected voids either into a beaker or a
113 graduated cylinder. Volumes were recorded, and a 50 mL aliquot from each void was sent to the
114 surface. All urine and blood samples were kept in a cooler on ice in the habitat before (and
115 during) ascent to the surface. The samples were also kept on ice aboard the boat when returning
116 to shore. 24-h pools were created based on void volumes, and aliquots were prepared and frozen
117 for analysis as soon as possible on shore.

118 For tests where storage would alter the results (e.g., malondialdehyde, hematocrit, and
119 hemoglobin), these were run in the laboratory facilities on shore. Others remained frozen on dry
120 ice until return to the Johnson Space Center in Houston.

121

122 *Biochemical Analyses*

123 Most analytical determinations were completed using standard, commercial techniques as
124 described previously (6). Hemoglobin, hematocrit (calculated), and mean corpuscular volume
125 were determined using a Coulter T890 instrument (Beckman Coulter, Brea, CA). Serum ferritin
126 and transferrin were analyzed using the Immulite (Diagnostics Products, Los Angeles, CA) and
127 Array 360 instruments, respectively (Beckman Coulter). Transferrin receptors were measured
128 using a commercially available ELISA (Ramco Laboratories, Houston, TX). RBC folate was
129 measured using a commercially available radioreceptor assay (Diagnostic Products, Los Angeles,
130 CA). Ferritin iron content was determined by ICP-MS using a method previously described (6).

131 Whole blood ionized calcium and electrolytes were determined using ion-sensitive electrode
132 techniques with a portable analyzer (i-STAT, Princeton, NJ) (6,10) . Despite attempts to use the
133 portable device *in situ* during the mission, the pressure differential did not allow for proper
134 functioning of the device. These tests were subsequently performed on samples once they were
135 returned to the surface.

136 Urine and serum total calcium was measured by inductively coupled plasma emission mass
137 spectrophotometry techniques (11). Serum intact parathyroid hormone was measured by RIA
138 (Nichols Institute Diagnostics, San Juan Capistrano, CA). Vitamin D metabolites 25-
139 hydroxyvitamin D and 1,25-dihydroxyvitamin D were also determined using commercially
140 available kits (DiaSorin, Stillwater, MN). Bone-specific alkaline phosphatase was measured by
141 ELISA (Quidel Corp, Santa Clara, CA, USA). Serum osteocalcin was measured by commercial
142 radioimmunoassay (Biomedical Technologies).

143 Urine samples were analyzed for collagen cross-links using commercially available kits
144 (METRA PYD and DPD EIA kits, Quidel Corp.; and Osteomark ELISA kit; Ostex International,

145 Inc., Seattle, WA, USA) as previously described (12). Crosslink data were expressed as nmol
146 excretion per day, as we have demonstrated that this reduces within-subject variability (13).

147 RBC superoxide dismutase, glutathione peroxidase, and serum oxygen-radical absorbance
148 capacity were measured spectrophotometrically using commercially available kits (Randox
149 Laboratories, Crumlin, UK). HPLC techniques (14) were used to determine 8-hydroxy-2'-
150 deoxyguanosine in urine. Plasma MDA was measured using a commercially available kit
151 (Calbiochem Lipid Peroxidation Assay kit, EMD Biosciences, Inc., San Diego, CA).

152 Serum total protein, cholesterol, triglycerides, sodium, potassium, chloride, aspartate
153 aminotransferase, alanine aminotransferase, RBC transaminase, and total alkaline phosphatase
154 were analyzed using a Beckman CX7 automated clinical chemistry system (Beckman Coulter,
155 Brea, CA). Serum albumin and transthyretin were analyzed using the Beckman Appraise and
156 Array 360 instruments, respectively (Beckman Coulter). Urine creatinine was analyzed on the
157 NexCT (Alfa Wassermann, West Caldwell, NJ).

158

159 *Statistical Analysis*

160 Data are reported as means \pm SD. Dietary data and biochemical data were analyzed using
161 repeated-measures analysis of variance (ANOVA) with a post-hoc Bonferroni test to determine
162 differences among groups. Statistical analyses were performed using SigmaStat (SPSS, Chicago,
163 IL).

164

165 **RESULTS**

166

167 *Dietary Intake*

168 Pre-dive dietary intakes were determined (mean \pm SD) for energy, fat, protein, calcium, and
169 iron (2100 ± 613 kcal, 84.7 ± 24.2 g, 83.1 ± 33.0 g, 774 ± 327 mg, and 19.7 ± 14.4 mg,
170 respectively) using a food frequency questionnaire. Energy intake was significantly lower than
171 the World Health Organization recommendations during the dive on MD 5, MD 6, and MD 11
172 (**Table 1**). Mid-dive means (\pm SD) were also determined for vitamin D, fat, protein, calcium,
173 and iron (5.46 ± 5.28 μ g, 63.3 ± 20 g, 77.5 ± 28 g, 1002 ± 387 mg, and 22.3 ± 9.56 mg,
174 respectively).

175

176 *Body Weights and Composition*

177 Body weights were significantly lower from pre dive weights on MD 7-14 ($P < 0.05$), and
178 higher than pre dive weights on R + 7 (**Table 1**). Body fat, bone mineral content, and lean body
179 mass were not different ($n=4$) when these measurements from R + 7 were compared with pre
180 dive measurements (**Table 1**).

181

182 *Hematology and general chemistry*

183 Hemoglobin and hematocrit were both decreased ($P < 0.05$) at R + 0 compared to pre dive
184 and MD7 (**Table 2**). Serum mean corpuscular volume (MCV) was significantly decreased ($P <$
185 0.05) on the last collection day post flight (R + 7) compared to in-dive (MD 7 and MD 12) and R
186 + 0 (**Table 2**). There was a significant decrease in serum iron post dive (R + 7) compared to in-
187 dive (MD 7 and MD 12).

188 Serum ferritin was significantly elevated both days in-id dive and R + 0 compared to pre and
189 post (R + 7) dive (**Table 2**). Similarly, serum ceruloplasmin tended to increase during the dive

190 and was significantly elevated R + 0 (**Table 3**). Transferrin receptors in serum tended to
191 decrease in-dive but the decrease compared to pre dive was only significant on R + 0 (Table 2).
192 Ferritin iron, transferrin, and ferritin saturation were unchanged throughout the study.

193 Triglycerides were elevated post dive (R + 7) compared to pre dive. Serum leptin tended to
194 decrease during the dive and was significantly different from pre dive on R + 0 (Table 3).

195 Electrolyte pools were also altered in response to conditions during NEEMO V. Sodium and
196 chloride excretion were decreased ($P < 0.05$) during the dive (MD 7 and MD 12) compared to
197 pre dive (**Table 4**), while urine excretion volume remained constant during the study. Serum
198 sodium concentration was significantly higher during the dive (MD 7 and MD 12) and after the
199 dive (R + 7) compared to pre dive ($P < 0.05$, Table 3). Whole blood sodium and
200 potassium.....showed the same changes? (data in table, or data not shown...)

201

202 *Calcium and bone metabolism*

203 Urinary calcium was significantly elevated post-dive (R + 8) compared to mid-dive (MD 12)
204 (**Table 5**). Serum total calcium was unaltered during the study; however, serum ionized calcium
205 was increased ($P < 0.05$) on MD 12 and post dive (R + 7) compared to pre dive (Table 5).

206 Urinary collagen crosslinks (NTX, PYD, and DPD) were unaffected during or after the dive.

207 Serum osteocalcin was significantly elevated post dive (R + 7) compared to in-dive (MD 7
208 and MD12), but other markers of bone formation including serum total alkaline phosphatase and
209 bone-specific alkaline phosphatase were unchanged during the study (Table 5). Similarly, there
210 was no effect on serum vitamin D metabolites, 25-hydroxy vitamin D or 1,25-dihydroxy vitamin
211 D (Table 5).

212

213 *Antioxidant status*

214 Urinary 8-hydroxy 2'-deoxyguanosine (8OHdG) excretion was significantly elevated during
215 the dive (MD 7 and MD12) compared to pre dive ($P < 0.05$) (**Table 6**). Other markers of
216 antioxidant status and function were also altered during and post dive, including whole blood
217 glutathione peroxidase (GPX) activity, superoxide dismutase (SOD) activity, and plasma
218 malondialdehyde (MDA). Whole blood GPX tended to decrease during the dive and R + 0 but it
219 was not significantly decreased until R + 7 (Table 6). Whole blood SOD was decreased MD 7,
220 and this significant decrease ($P < 0.05$) compared to the pre dive continued throughout the
221 remainder of the study (MD 12, R + 0, and R + 7). Plasma MDA was significantly decreased
222 post dive (R + 0 and R + 7) compared to pre dive. Red blood cell glutathione reductase activity
223 was decreased ($P < 0.05$) at the latter part of the dive (MD 12 and R + 0), but was returned to pre
224 dive concentrations 7 d after the dive (Table 3).

225

226 **DISCUSSION**

227 Limitations on resources (e.g., time, power, volume, up/down mass) for spaceflight research
228 necessitate the development of Earth-based analogs. The underwater isolation of the NEEMO
229 missions provides one such analog of spaceflight, with obvious similarities, along with obvious
230 limitations. The study we report here clearly identifies this as a valuable analog environment,
231 with results that resemble many aspects of spaceflight beyond the direct nutritional implications
232 (e.g., dietary intake). In further defining the changes that occurred in crew members, we will be
233 better able to propose, design, and test countermeasures for future missions.

234 The hematological findings are striking, and extend those from earlier dive studies, as well as
235 apply to hematological changes seen during spaceflight. Reductions in hemoglobin

236 concentration and increases in serum ferritin concentration are well established in deep saturation
237 dives (depths up to 660 m, 31 – 67 atm) (15-17). These same effects were observed after the 14-
238 d shallow saturation dive described here (14.3 m, 2.5 atm). Reduced hemoglobin concentrations
239 suggest a reduction in red blood cell mass, which could be due to decreased production of new
240 red blood cells, as seen in spaceflight (18), or destruction of existing red blood cells by oxidative
241 damage (15,19).

242 Increased serum ferritin in-dive and decreased transferrin receptors R + 0 were also observed
243 and would be expected when iron stores and intracellular iron availability are high. It is likely
244 that the increased oxygen availability, induced by the increased atmospheric pressure,
245 contributed to a decreased need for red blood cells, and iron pools were consequently shifted
246 from hemoglobin to a storage form. This process, termed neocytolysis, has been documented in
247 spaceflight (20,21), as well as in subjects traveling from high to low altitude (22).

248 While ferritin iron content did not increase along with the increased serum ferritin, ferritin
249 iron and serum iron both tended to go up during the dive. One possibility for lack of significance
250 is the small sample size (n = 6 for pre dive, MD 7, R + 0, and R + 7; n = 5 for MD 12). Another
251 possibility is that the increase in total serum ferritin is indicative of recruitment of ferritin from
252 preexisting stores, and that the time course is too short for enrichment of ferritin with excess iron
253 to alter the reflection in the serum. There is also a possibility that the changes of serum ferritin
254 during the dive were due to an acute inflammatory response since there were other indications
255 that such a response might have occurred. Other acute phase proteins tended to go up during the
256 dive. While not significant, serum C-reactive protein tended to be elevated during the dive
257 compared to pre and post dive. The large variances prevented these findings from being
258 significant. Again, we are limited with the very small sample size in this study. Furthermore,

259 other studies suggest that oxidative stress is increased during the acute inflammatory phase of
260 many illnesses (24,25), which was also observed in one subject prior to the dive.

261 Alterations in antioxidant markers were hypothesized due to the hyperbaric environment.
262 Along with the increased 8OHdG excretion observed during the dive, decreased activities of
263 GPX and SOD post (GPX and SOD) and in-dive (SOD) imply increased oxidative stress. A
264 number of other parameters (besides the environment) could have contributed to this, including
265 changes in nutrient intake or changes in stress hormones. The significant decrease in MDA
266 suggests that lipid peroxidation is decreased in and post dive compared to pre dive, which does
267 not support the theory of increased oxidative damage. This decrease is not easily explained since
268 we would have expected to see similar changes during the dive for 8OHdG and MDA. Pre dive
269 measurements for all parameters are averages of measurements recorded twice before the dive,
270 and there appeared to be differences between the two collection points (pre dive day 12 for MDA
271 was high compared to pre dive day 1; specifically 1.25 ± 0.96 and 0.26 ± 0.18 $\mu\text{mol/L}$ for pre
272 dive days 12 and 1, respectively). If only pre dive day 1 was used for comparison (instead of the
273 average of the two), MDA then tended to increase during the dive compared to pre and post dive.

274 Mean body weights were significantly lower than pre dive weights during the latter part of the
275 dive (MD 7-14). During the dive, energy intakes were lower than World Health Organization
276 recommendations (Table 1). This is a similar phenomenon that consistently occurs during
277 spaceflight (6,26,27), and explains why body weights were concurrently decreased. Serum leptin
278 was measured in these individuals and we found that these concentrations tended to go down
279 during the dive and were significantly decreased by the last day (R + 0). Leptin is normally
280 involved in the regulation of food intake and in the maintenance of energy balance, but its role in
281 the decreased energy intake in this study is unknown and warrants further investigation. Other

282 studies have linked decreased leptin concentration with periods of intense exercise, possibly
283 indicative of increased stress or inflammation (28,29). Again, consistent with other findings
284 outlined above, the decreased leptin observed here may support the presence of an acute
285 inflammatory response during the dive.

286 Despite increased pressure in the habitat, there was no evidence for alterations in bone
287 formation/resorption during the dive. While osteocalcin was significantly higher post dive (R +
288 7) compared to in-dive (MD 7 and MD 12), other bone formation markers in the serum,
289 including alkaline phosphatase and bone-specific alkaline phosphatase, were unchanged during
290 the study. Bone resorption markers were unchanged during the dive. Parathyroid hormone and
291 vitamin D concentrations tended to decrease, but not significantly. Both of these indices might
292 have reached statistical significance with a longer mission (due to lack of ultraviolet light
293 exposure) or with additional subjects. Furthermore, these findings enhance our recent
294 observations that lower body negative pressure (LBNP) can mitigate disuse-induced bone
295 resorption (30). The current study, one of whole body positive pressure, suggests that the
296 findings with LBNP may be more related to circulatory changes than to pressure itself. Such
297 suggestions that circulatory influences may impact weightlessness-induced bone loss are not new
298 (31,32).

299 It is evident that there are indeed many physiological and nutritional changes that occurred
300 during NEEMO V that are also commonly observed during spaceflight. Changes in nutritional
301 status during spaceflight are of critical concern for future long duration space travel, and
302 spaceflight analogs such as NEEMO V may be increasingly important to further investigate
303 potential countermeasures.

304

305

306 Acknowledgements

307 We thank the NEEMO V crew for their participation in this study. The authors also wish to
308 thank E. Lichar Dillon, Diane E. DeKerlegand, and Patricia L. Gillman of the Johnson Space
309 Center Nutritional Biochemistry Laboratory for their support in completing the analytical
310 measurements reported here. We thank Gaurang Patel for assistance with hardware preparation
311 and crew training to support this investigation; Karin Bergh for her assistance with Crew
312 Procedures development and training; and Mary Jane Maddocks for assistance with the DEXA
313 determinations. We would like to thank Clarence P. Alfrey for insightful discussions regarding
314 ferritin and hematological changes reported here. We also thank Jane Krauhs for editorial
315 assistance.

316

317

318

319 **REFERENCES**

- 320 1. Leach, C. S., Dietlein, L. F., Pool, S. L. & Nicogossian, A. E. (1990) Medical
321 considerations for extending human presence in space. *Acta Astronaut* 21: 659-666.
- 322 2. Stein, T. P. (2002) Space flight and oxidative stress. *Nutrition* 18: 867-871.
- 323 3. Alfrey, C. P., Udden, M. M., Leach-Huntoon, C., Driscoll, T. & Pickett, M. H. (1996)
324 Control of red blood cell mass in spaceflight. *J Appl Physiol* 81: 98-104.
- 325 4. Smith, S. M., Uchakin, P. N. & Tobin, B. W. (2002) Space flight nutrition research:
326 platforms and analogs. *Nutrition* 18: 926-929.

- 327 5. Leach, C. S. (1992) Biochemical and hematologic changes after short-term space flight.
328 Microgravity Q 2: 69-75.
- 329 6. Smith, S. M., Davis-Street, J. E., Rice, B. L., Nillen, J. L., Gillman, P. L. & Block, G.
330 (2001) Nutritional status assessment in semiclosed environments: ground-based and space flight
331 studies in humans. J Nutr 131: 2053-2061.
- 332 7. Stowe, R. P., Mehta, S. K., Ferrando, A. A., Feedback, D. L. & Pierson, D. L. (2001)
333 Immune responses and latent herpesvirus reactivation in spaceflight. Aviat Space Environ Med
334 72: 884-891.
- 335 8. Leach, C. S. & Rambaut, P. C. (1975) Endocrine responses in long-duration manned
336 space flight. Acta Astronaut 2: 115-127.
- 337 9. Macho, L., Koska, J., Ksinantova, L., Pacak, K., Hoff, T., Noskov, V. B., Grigoriev, A.
338 I., Vigas, M. & Kvetnansky, R. (2003) The response of endocrine system to stress loads during
339 space flight in human subject. Adv Space Res 31: 1605-1610.
- 340 10. Smith, S. M., Davis-Street, J. E., Fontenot, T. B. & Lane, H. W. (1997) Assessment of a
341 portable clinical blood analyzer during space flight. Clin Chem 43: 1056-1065.
- 342 11. Hsiung, C. S., Andrade, J. D., Costa, R. & Ash, K. O. (1997) Minimizing interferences in
343 the quantitative multielement analysis of trace elements in biological fluids by inductively
344 coupled plasma mass spectrometry. Clin Chem 43: 2303-2311.
- 345 12. Smith, S. M., Nillen, J. L., Leblanc, A., Lipton, A., Demers, L. M., Lane, H. W. & Leach,
346 C. S. (1998) Collagen cross-link excretion during space flight and bed rest. J Clin Endocrinol
347 Metab 83: 3584-3591.
- 348 13. Smith, S. M., Dillon, E. L., DeKerlegand, D. E. & Davis-Street, J. E. (2004) Variability
349 of Collagen Crosslinks: Impact of Sample Collection Period. Calcif Tissue Int.

- 350 14. Bogdanov, M. B., Beal, M. F., McCabe, D. R., Griffin, R. M. & Matson, W. R. (1999) A
351 carbon column-based liquid chromatography electrochemical approach to routine 8-hydroxy-2'-
352 deoxyguanosine measurements in urine and other biologic matrices: a one-year evaluation of
353 methods. *Free Radic Biol Med* 27: 647-666.
- 354 15. Thorsen, E., Haave, H., Hofso, D. & Ulvik, R. J. (2001) Exposure to hyperoxia in diving
355 and hyperbaric medicine--effects on blood cell counts and serum ferritin. *Undersea Hyperb Med*
356 28: 57-62.
- 357 16. Cotes, J. E., Davey, I. S., Reed, J. W. & Rooks, M. (1987) Respiratory effects of a single
358 saturation dive to 300 m. *Br J Ind Med* 44: 76-82.
- 359 17. Gilman, S. C., Biersner, R. J. & Piantadosi, C. (1982) Serum ferritin increases during
360 deep saturation dives. *Aviat Space Environ Med* 53: 1014-1016.
- 361 18. Alfrey, C. P., Udden, M. M., Huntoon, C. L. & Driscoll, T. (1996) Destruction of newly
362 released red blood cells in space flight. *Med Sci Sports Exerc* 28: S42-44.
- 363 19. Goldstein, J. R., Mengel, C. E., Carolla, R. L. & Ebbert, L. (1969) Relationship between
364 tocopherol status and in vivo hemolysis caused by hyperoxia. *Aerosp Med* 40: 132-135.
- 365 20. Rice, L. & Alfrey, C. P. (2000) Modulation of red cell mass by neocytolysis in space and
366 on Earth. *Pflugers Arch* 441: R91-94.
- 367 21. Alfrey, C. P., Rice, L., Udden, M. M. & Driscoll, T. B. (1997) Neocytolysis:
368 physiological down-regulator of red-cell mass. *Lancet* 349: 1389-1390.
- 369 22. Rice, L., Ruiz, W., Driscoll, T., Whitley, C. E., Tapia, R., Hachey, D. L., Gonzales, G. F.
370 & Alfrey, C. P. (2001) Neocytolysis on descent from altitude: a newly recognized mechanism for
371 the control of red cell mass. *Ann Intern Med* 134: 652-656.

- 372 23. Doran, G. R., Chaudry, L., Brubakk, A. O. & Garrard, M. P. (1985) Hyperbaric liver
373 dysfunction in saturation divers. *Undersea Biomed Res* 12: 151-164.
- 374 24. Diplock, A. T. (1998) Defense against reactive oxygen species. *Free Radic Res* 29: 463-
375 467.
- 376 25. Tomkins, A. (2003) Assessing micronutrient status in the presence of inflammation. *J*
377 *Nutr* 133: 1649S-1655S.
- 378 26. Stein, T. P., Leskiw, M. J., Schluter, M. D., Hoyt, R. W., Lane, H. W., Gretebeck, R. E.
379 & LeBlanc, A. D. (1999) Energy expenditure and balance during spaceflight on the space shuttle.
380 *Am J Physiol* 276: R1739-1748.
- 381 27. Stein, T. P., Leskiw, M. J. & Schluter, M. D. (1996) Diet and nitrogen metabolism during
382 spaceflight on the shuttle. *J Appl Physiol* 81: 82-97.
- 383 28. Desgorces, F. D., Chennaoui, M., Gomez-Merino, D., Drogou, C. & Guezennec, C. Y.
384 (2003) Leptin response to acute prolonged exercise after training in rowers. *Eur J Appl Physiol*.
- 385 29. Baylor, L. S. & Hackney, A. C. (2003) Resting thyroid and leptin hormone changes in
386 women following intense, prolonged exercise training. *Eur J Appl Physiol* 88: 480-484.
- 387 30. Smith, S. M., Davis-Street, J. E., Fesperman, J. V., Calkins, D. S., Bawa, M., Macias, B.
388 R., Meyer, R. S. & Hargens, A. R. (2003) Evaluation of treadmill exercise in a lower body
389 negative pressure chamber as a countermeasure for weightlessness-induced bone loss: a bed rest
390 study with identical twins. *J Bone Miner Res* 18: 2223-2230.
- 391 31. Hillsley, M. V. & Frangos, J. A. (1994) Bone tissue engineering: the role of interstitial
392 fluid flow. *Biotechnol Bioeng* 43: 573-581.

393 32. Colleran, P. N., Wilkerson, M. K., Bloomfield, S. A., Suva, L. J., Turner, R. T. & Delp,
394 M. D. (2000) Alterations in skeletal perfusion with simulated microgravity: a possible
395 mechanism for bone remodeling. *J Appl Physiol* 89: 1046-1054.

396

397 Table 1. Body weight and dietary intake data from NEEMO V¹.

	PRE	MD2	MD3	MD4	MD5	MD6	MD7	MD8	MD9	MD10	MD11
Energy Intake, kcal	-	2590 ± 613	2660 ± 925	2600 ± 851	2010 ± 886**	1790 ± 654**	2384 ± 658	2380 ± 510	2550 ± 471	2400 ± 688	2110 ± 362**
Energy Intake (% WHO)	-	90.0 ± 7.2	92.2 ± 21.1	89.6 ± 16.2	71.4 ± 27.9	60.9 ± 12.9	83.1 ± 17.8	83.3 ± 10.6	91.0 ± 17.4	82.5 ± 9.5	75.1 ± 12.4
Water Intake, mL	-	3000 ± 989	3260 ± 912	2510 ± 751	1960 ± 689	1910 ± 1140	2410 ± 877	2790 ± 810	3810 ± 1960	2680 ± 1210	2200 ± 634
BW (kg)	76.0 ± 16.1	75.2 ± 16.6	75.4 ± 15.9	75.1 ± 16.2	75.0 ± 16.0	75.0 ± 15.5	74.6 ± 15.7	74.3 ± 15.6	74.5 ± 15.9	74.6 ± 15.6	74.2 ± 15.8
Body Mass (DEXA) (kg)	69.9 ± 17.3	-	-	-	-	-	-	-	-	-	-
Body Fat (kg)	15.3 ± 2.3	-	-	-	-	-	-	-	-	-	-
BMC	2.5 ± 0.7	-	-	-	-	-	-	-	-	-	-
LBM (kg)	52.1 ± 14.5	-	-	-	-	-	-	-	-	-	-

398

399 ¹BW, body weight; BMC, bone mineral content; LBM, lean body mass. Values are means ± SD,

400 n = 6. **Energy intake is significantly different from WHO recommendations (P < 0.05).

401 *Significantly different from pre dive (P < 0.05).

402 Table 2. Hemotologic, iron, and folate status indicators before, during, and after NEEMO V¹.

	Pre	MD 7	MD 12	R + 0	R + 7
Serum Hgb, g/L	136 ± 15 ^{ac}	138 ± 10 ^{ac}	137 ± 14 ^{cd}	128 ± 13 ^{bd}	131 ± 13 ^{cd}
Serum HCT	0.41 ± 0.04 ^{ac}	0.41 ± 0.03 ^{ac}	0.40 ± 0.04 ^{cd}	0.38 ± 0.04 ^{bd}	0.40 ± 0.04 ^{cd}
Serum MCV, fL	91 ± 3 ^{ab}	92 ± 3 ^a	92 ± 4 ^a	92 ± 3 ^a	90 ± 2 ^{bc}
Serum Iron, umol/L	19 ± 7 ^{ac}	26 ± 10 ^a	27 ± 10 ^a	22 ± 5 ^{ac}	12 ± 4 ^{bc}
Ferritin Iron, umol/L	0.34 ± 0.15	0.48 ± 0.19	0.44 ± 0.17	0.47 ± 0.17	0.32 ± 0.12
Serum Ferritin, ug/L	102 ± 63 ^a	168 ± 82 ^b	219 ± 98 ^b	196 ± 92 ^b	117 ± 70 ^a
Ferritin Saturation, %	22.8 ± 9.2	18.2 ± 8.7	12.0 ± 3.2	14.6 ± 3.8	18.6 ± 8.5
Transferrin Receptors, ug/mL	4.8 ± 1.3 ^{ac}	4.6 ± 1.1 ^{cd}	4.3 ± 0.8 ^{cd}	3.9 ± 0.9 ^{bd}	4.1 ± 1.0 ^{cd}
Transferrin, g/L	2.63 ± 0.18	2.66 ± 0.29	2.65 ± 0.14	2.53 ± 0.24	2.62 ± 0.18
RBC Folate, nmol/L	1705 ± 486	1598 ± 575	1683 ± 365	1445 ± 486	1554 ± 429

403

404 ¹Hgb, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; RBC, red blood cell.

405 Values are means ± SD, n = 6 (n = 5 on MD 12 for all parameters, except transferrin receptors

406 where n = 6 for all days). Significant differences in rows are represented by different letters (P <

407 0.05).

408 Table 3. General blood chemistry before, during, and after NEEMO V¹.

	Pre	MD 7	MD 12	R + 0	R + 7
Serum Sodium, mmol/L	138 ± 2 ^a	141 ± 2 ^b	141 ± 2 ^b	139 ± 1 ^a	141 ± 2 ^b
Serum Potassium, mmol/L	4.2 ± 0.3	4.1 ± 0.2	4.2 ± 0.7	3.9 ± 0.3	4.3 ± 0.2
Serum Chloride, mmol/L	106 ± 2	106 ± 3	105 ± 3	105 ± 2	107 ± 3
Serum Creatinine, umol/L	94 ± 13	94 ± 13	77 ± 40	93 ± 17	94 ± 16
Serum Triglyceride, mmol/L	1.03 ± 0.34	1.07 ± 0.38	1.13 ± 0.62	1.54 ± 0.55	1.72 ± 1.00
Serum RBP, mg/L	67.4 ± 7.21	58.8 ± 17.9	59.3 ± 11.4	55.0 ± 11.2	65.3 ± 13.4
RBC GSH Activity, % act	13.9 ± 9.95	7.2 ± 10.5	5.7 ± 5.0	6.0 ± 7.6	10.4 ± 4.9
RBC Transaminase act, % act	81.6 ± 13.4	86.0 ± 15.4	79.5 ± 16.6	86.7 ± 15.4	82.1 ± 13.8
Serum ATL, U/L	18.4 ± 7.0	13.8 ± 6.2	16.2 ± 4.8	14.2 ± 3.5	18.8 ± 6.9
Serum AST, U/L	25.9 ± 2.6	29.7 ± 4.6	29.6 ± 10.6	26.2 ± 3.9	25.3 ± 5.8
Serum Ceruloplasmin, mg/L	430 ± 130 ^a	470 ± 150 ^{ab}	480 ± 120 ^{ab}	520 ± 120 ^b	500 ± 140 ^{ab}
Serum Transthyretin, mg/L	305 ± 58	285 ± 24	312 ± 22	305 ± 38	327 ± 59
Serum Cholesterol, mmol/L	5.15 ± 0.67	5.14 ± 1.10	4.26 ± 2.26	4.78 ± 0.86	5.31 ± 0.91
Serum pH	7.4 ± 0.02	7.4 ± 0.02	7.4 ± 0.05	7.4 ± 0.02	7.4 ± 0.04
Total protein, g/L	68 ± 4	70 ± 3	70 ± 7	70 ± 3	69 ± 4
Albumin, g/L	43 ± 3	46 ± 2	45 ± 3	45 ± 3	45 ± 3
Leptin, ng/mL	5.8 ± 3.5 ^{ab}	4.2 ± 2.6 ^b	2.7 ± 1.2 ^b	2.3 ± 1.1 ^c	5.6 ± 2.4 ^{bd}
CRP, mg/L	1.8 ± 1.9	11.9 ± 18.1	12.4 ± 23.3	4.7 ± 7.4	2.1 ± 2.4

409

410 ¹RBP, retinol binding protein; RBC, red blood cell; GSH, glutathione reductase; ALT, alanine

411 aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein. Values are means

412 ± SD, n = 6 (n = 5 on MD 12 for all parameters except for serum RBP, where n = 6 for all days).

413 Significant differences in rows are represented by different letters (P < 0.05).

414 Table 4. General urine chemistry before, during, and after NEEMO V¹.

	Pre	MD 7	MD 12	R + 0	R + 1	R + 7	R + 8
Urine pH	6.0 ± 0.16	6.22 ± 0.41	6.25 ± 0.33	6.07 ± 0.47	6.46 ± 0.45	6.21 ± 0.55	6.04 ± 0.31
Urine excretion volume, mL	2160 ± 676	1970 ± 1260	2410 ± 944	2670 ± 1390	1670 ± 647	2110 ± 1040	2620 ± 1940
Urine Sodium, mmol/d	182 ± 21 ^a	120 ± 71 ^b	106 ± 44 ^b	98.7 ± 32.1	124 ± 42	163 ± 31	191 ± 58
Urine Potassium, mmol/d	62.2 ± 15.7 ^{ab}	47.3 ± 15.0 ^a	53.0 ± 18.5 ^{ab}	46.8 ± 18.2	53.8 ± 24.1	72.5 ± 25.2	64.8 ± 20.7
Urine Chloride, mmol/d	176 ± 16 ^a	98.5 ± 60.4 ^b	90.2 ± 31.9 ^b	87.7 ± 30.6	107 ± 24	159 ± 25	193 ± 69
Urine 3MH, umol/d	245 ± 122	242 ± 138	222 ± 116	230 ± 93	270 ± 104	271 ± 112	269 ± 114
Urine Iodine, mmol/d	2.46 ± 0.91	2.12 ± 0.84	1.77 ± 0.71	2.68 ± 1.13	1.80 ± 0.29	2.18 ± 0.96	2.60 ± 1.39
Urine Mg, mmol/d	3.89 ± 1.05	4.34 ± 1.39	3.78 ± 1.44	4.67 ± 1.67	3.41 ± 1.96	4.43 ± 0.94	5.06 ± 1.60
Urine Phos, mmol/d	30 ± 7	34 ± 11	33 ± 12	27 ± 10	23 ± 8	29 ± 11	29 ± 6
Urine Creatinine, mmol/d	16.3 ± 3.7	15.2 ± 5.2	17.5 ± 5.2	18.2 ± 4.0	13.5 ± 7.4	16.3 ± 4.0	16.1 ± 3.5

415

416 ¹3MH, 3-methylhistidine. Values are means ± SD, n = 6 (n = 5 on R + 1). Significant

417 differences in rows are represented by different letters (P < 0.05).

418 Table 5. Calcium and bone markers before, during, and after NEEMO V¹.

	Pre	MD 7	MD 12	R + 0	R + 1	R + 7	R + 8
Serum iPTH, pg/mL	31.1 ± 7.82	25.8 ± 9.72	24.3 ± 6.87	28.8 ± 10.2	-	29.6 ± 9.81	-
Serum Osteocalcin, ng/mL	9.30 ± 2.10 ^{ac}	7.43 ± 1.02 ^a	7.75 ± 1.46 ^a	8.35 ± 1.73 ^{ac}	-	10.7 ± 2.90 ^{bc}	-
Alk P ^{ase}							
Serum total Alk Phosphata	57.7 ± 22.0	61.0 ± 17.7	66.6 ± 20.0	61.7 ± 22.3	-	61.3 ± 21.5	-
Serum BSAP, U/L	21.7 ± 7.80	20.7 ± 7.20	21.4 ± 8.60	21.7 ± 8.06	-	19.7 ± 7.45	-
Serum 25 OH Vit D, nmol/L	92 ± 23	86 ± 30	81 ± 18	86 ± 18	-	81 ± 24	-
Serum 1,25 OH Vit D, pmol/L	211 ± 52.4	212 ± 105	221 ± 80.6	198 ± 108	-	201 ± 64.1	-
Calcium							
Serum TCa, mmol/L	2.56 ± 0.11	2.70 ± 0.18	2.57 ± 0.15	2.57 ± 0.10	-	2.67 ± 0.22	-
Serum iCa, mmol/L	1.18 ± 0.03	1.23 ± 0.05	1.26 ± 0.02 [*]	1.21 ± 0.03	-	1.21 ± 0.03 [*]	-
Urine Ca, mmol/L	5.49 ± 0.73 ^{ac}	4.83 ± 1.85 ^{ac}	3.98 ± 0.91 ^a	5.13 ± 1.51 ^{ac}	4.92 ± 1.21 ^{ac}	6.12 ± 2.33 ^{ac}	6.82 ± 2.18 ^{bc}
DPD, nmol/d	63.9 ± 7.4	73.7 ± 24.9	70.2 ± 20.2	61.6 ± 15.5	60.3 ± 8.6	66.8 ± 17.3	57.0 ± 19.8
NTX, nmol/d	464 ± 235	690 ± 384	480 ± 287	430 ± 208	499 ± 271	539 ± 363	556 ± 240
PYD, nmol/d	256 ± 51	307 ± 85	292 ± 78	297 ± 98	224 ± 68	285 ± 87	260 ± 89

419

420

421 ¹iPTH, intact parathyroid hormone; Alk Phosphatase, alkaline phosphatase; BSAP, bone-specific

422 alkaline phosphatase; DPD, deoxypyridinoline; NTX, n-telopeptide; PYD, pyridinium crosslinks.

423 Values are means ± SD, n = 6 (n = 5 on MD 12 fortotal alkaline phosphatase and n = 5 on R + 1

424 for DPD, NTX, and PYD). Significant differences in rows are represented by different letters (P

425 < 0.05). *Significantly different from pre dive (P < 0.05).

426 Table 6. Antioxidant/oxidative damage indices from NEEMO V crew members¹.

	Pre	MD 7	MD 12	R + 0	R + 7
8(OH)dG, ug/d	5.71 ± 1.28 ^a	7.25 ± 2.26 ^{bca}	7.41 ± 2.12 ^{bd}	6.83 ± 2.44	5.79 ± 1.52
GPX, U/g Hgb	63.8 ± 6.4 ^a	54.1 ± 9.1 ^{ab}	58.6 ± 9.7 ^{ab}	53.1 ± 9.2 ^{ab}	48.1 ± 7.2 ^b
MDA, umol/L	0.75 ± 0.46 ^a	0.61 ± 0.22 ^{ab}	0.60 ± 0.25 ^{ab}	0.26 ± 0.13 ^b	0.20 ± 0.05 ^b
SOD, U/g Hgb	1240 ± 185 ^a	877 ± 173 ^b	912 ± 185 ^b	1030 ± 170 ^b	997 ± 101 ^b
TAC, mmol/L	1.12 ± 0.03	1.15 ± 0.15	1.39 ± 0.47	1.06 ± 0.09	1.12 ± 0.06

427

428 ¹8(OH)dG, 8-hydroxy-2'-deoxyguanosine; GPX, glutathione peroxidase; MDA,

429 malondialdehyde; SOD, superoxide dismutase; TAC, total antioxidant capacity. Values are

430 means ± SD, n = 6 (n = 5 for GPX, MDA, and SOD for MD 12 and n = 5 for 8(OH)dG on R +

431 1). Significant differences in rows are represented by different letters (P < 0.05).

432